ERBB2 and colorectal carcinoma: Our study demonstrated that approximately 75.6% of patients with HER2 amplified CRC had RAS/RAF wild type, suggesting that they may benefit from a combination therapy of anti-HER2 inhibitors in advanced stages of the disease.